Nurix Therapeutics

1700 Owens Street
Suite 205
San Francisco
California
94158
United States

Tel: 415-660-5320

About Nurix Therapeutics

Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels.

Nurix’s wholly owned pipeline comprises targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California.

104 articles about Nurix Therapeutics

Nurix Therapeutics Reports Dosing of First Patient in Phase 1 Clinical Trial of NX-5948, a Selective BTK Degrader, in Development for B-cell Leukemias and Lymphomas

5/17/2022

Nurix Therapeutics, Inc. announced that the first patient has been dosed in its Phase 1a/1b study to evaluate orally available small molecule NX-5948, a potent and selective degrader of Bruton’s tyrosine kinase in patients with relapsed B-cell malignancies.
Nurix Therapeutics Announces Participation in the 2022 RBC Capital Markets Global Healthcare Conference

5/11/2022

Nurix Therapeutics, Inc. announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference on Wednesday, May 18th, 2022 at 11:00 a.m. ET.
AACR: Advances in Immune System Stimulation and Cell Transplants Favor Oncology

4/15/2022

BioSpace looked at some of the efforts to improve the host system’s immune response, as well as others to improve allogeneic or autologous cell transplants.
Clinical Catch-Up: COVID-19, AAN, ACC

4/11/2022

It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look.
Nurix Therapeutics Reports Fiscal First Quarter 2022 Financial Results and Provides a Corporate Update

4/7/2022

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today reported financial results for the first quarter ended February 28, 2022 and provided a corporate update.
Nurix Therapeutics Doses First Patient in Phase 1 Clinical Trial of DeTIL-0255, a Drug-Enhanced Cell Therapy for the Treatment of Patients with Solid Tumors

4/5/2022

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company developing targeted protein modulation drugs, announced that the first patient has been dosed in its Phase 1 clinical trial of DeTIL-0255, a drug-enhanced tumor infiltrating lymphocyte therapy and the lead candidate in its cellular therapy portfolio.
Nurix Therapeutics Announces Participation in the 21st Annual Needham Virtual Healthcare Conference

4/4/2022

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference.
Nurix Therapeutics Awarded Innovation Passport for Entry into Innovative Licensing and Access Pathway (ILAP) in the United Kingdom for NX-1607

3/29/2022

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has awarded the innovative medicine designation, the Innovation Passport, for NX-1607 in the treatment of patients with advanced solid tumors.
Nurix Therapeutics to Participate in Upcoming Investor Conferences in March 2022

3/9/2022

Nurix Therapeutics, Inc., a biopharmaceutical company developing targeted protein modulation drugs, announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in the following conferences in March:.
Nurix Therapeutics to Present Preclinical Data from Its Novel BTK Degrader (NX-2127) and CBL-B Inhibitor (NX-0255) Programs at the American Association for Cancer Research Annual Meeting

3/8/2022

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that preclinical data supporting its NX-2127 and DeTIL-0255 clinical programs will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting.
Nurix Therapeutics Announces Participation in the 11th Annual SVB Leerink Global Healthcare Conference

2/10/2022

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference.
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Corporate Update

1/27/2022

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today reported financial results for the fourth quarter and fiscal year ended November 30, 2021 and provided a corporate update.
Nurix Therapeutics Advances Clinical and Preclinical Pipeline and Outlines 2022 Catalysts

1/10/2022

Nurix Therapeutics, Inc., a biopharmaceutical company developing targeted protein modulation drugs, outlined key objectives and anticipated milestones for 2022 and provided an overview of recent progress.
Nurix Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference

1/3/2022

Nurix Therapeutics, Inc. announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix will present an overview of corporate performance in 2021 and major goals for 2022 at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 5:15 pm ET.
Clinical Catch-Up: December 11-17

12/20/2021

It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look.
Nurix Therapeutics Announces Regulatory Clearance to Initiate Phase 1 Clinical Trial of NX-5948 and Presents New Preclinical Data at the American Society of Hematology Annual Meeting

12/12/2021

Nurix Therapeutics, Inc., a biopharmaceutical company developing targeted protein modulation drugs, announced the grant of a Clinical Trial Authorization for NX-5948, a potent and selective degrader of Bruton’s tyrosine kinase and the second drug candidate in Nurix’s BTK degradation program.
Nurix Therapeutics Presents Beneficial Effects of CBL-B Inhibition on Human Tumor Infiltrating Lymphocytes at SITC Conference

11/12/2021

Nurix Therapeutics, Inc. today announced the presentation of preclinical studies demonstrating that its CBL-B inhibitor, NX-0255, enhances the number and quality of T cells expanded from tumors for use in tumor infiltrating lymphocyte (TIL) therapy.
Nurix Therapeutics Announces IND clearance for DeTIL-0255, a drug-enhanced autologous T cell therapy for the potential treatment of a variety of solid tumors

11/12/2021

Nurix Therapeutics, Inc. today announced that the Food and Drug Administration (FDA) has cleared Nurix’s Investigational New Drug Application (IND) for its lead cell therapy product candidate DeTIL-0255
Nurix Therapeutics to Participate in Upcoming Investor Conferences - Nov 09, 2021

11/9/2021

Nurix Therapeutics, Inc., a biopharmaceutical company developing targeted protein modulation drugs, announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in fireside chats at the following conferences in November:.
Clinical Catch-Up: October 25-29

11/1/2021

Yet another busy week for clinical trial news. Here’s a look.